Dr. Matt
Coffey, Oncolytics' President & Chief Executive Officer,
to present on the clinical progress of using reovirus as an
immuno-oncology viral agent to treat cancer
CALGARY and SAN DIEGO, CA, Dec. 4,
2017 /PRNewswire/ - Oncolytics Biotech® Inc.
(TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech
company developing REOLYSIN®, also known as pelareorep,
an intravenously delivered immuno-oncolytic virus that activates
the innate and adaptive immune systems to turn 'cold' tumors 'hot',
today announced that it will present at the Oncolytic Virotherapy
Summit. Dr. Matt Coffey,
Oncolytics' President and Chief Executive Officer, will present on
Wednesday, December 6 at 11:00 a.m. ET as part of a panel presentation and
then present specifically on pelareorep in a Clinical Case Study
presentation at 2:30 p.m. ET on the
same day. The conference takes place on December 5th, 6th and
7th in Miami,
Florida.
"The Oncolytic Virotherapy Summit offers us another opportunity
to highlight our extensive experience with pelareorep in the clinic
and to illustrate its ability to induce an inflamed tumor phenotype
amongst our peers and for potential partners," said Dr. Coffey.
"Our clinical experience with pelareorep has led us to favorable
feedback from the FDA following our end-of-phase 2 meeting which
helps us define a clear regulatory path in metastatic breast cancer
and a single 400-patient phase 3 registration study. Our phase 3
protocol will be made available following evaluation and completion
of discussions with clinical advisors, potential partners and the
EMA."
The panel presentation: "How Can We Improve The Efficacy of
Oncolytic Virotherapies?", also including management from
PsiOxus Therapeutics, Vyriad and Replimune Group, will cover:
- Viral modulation of the tumor microenvironment
- Increasing the viral impact with activated immune
responses
- Combination drug therapies to stimulate the immune response and
prevent immunosuppression
- Viral delivery for largest impact
Dr. Coffey's individual presentation: "Clinical
Progress and Robust Safety Findings of Using Reovirus as an
Immuno-Oncology Viral Agent to Treat Cancer", will
highlight:
- The role of REOLYSIN in the activation of the immune system and
the induction of an inflamed tumor phenotype in the tumor
microenvironment
- Overall survival data from the Company's randomized phase 2
metastatic breast cancer study
- The largest pooled safety database of any oncolytic virus
About REOLYSIN/Pelareorep
REOLYSIN, also known as
pelareorep, is a non-pathogenic, proprietary isolate of the
unmodified reovirus: a first-in-class intravenously delivered
immuno-oncolytic virus for the treatment of solid tumors and
hematological malignancies. The compound induces selective tumor
lysis and promotes an inflamed tumor phenotype through innate and
adaptive immune responses to treat a variety of cancers.
About Oncolytics Biotech Inc.
Oncolytics is a
biotechnology company developing REOLYSIN, also known as
pelareorep, an intravenously delivered immuno-oncolytic virus. The
compound induces selective tumor lysis and promotes an inflamed
tumor phenotype – turning 'cold' tumors 'hot' – through innate and
adaptive immune responses to treat a variety of cancers.
Oncolytics' clinical development program emphasizes three pillars:
chemotherapy combinations to trigger selective tumor lysis;
immuno-therapy combinations to produce adaptive immune responses;
and immune modulator (IMiD) combinations to facilitate innate
immune responses. Oncolytics is currently planning its first
registration study in metastatic breast cancer, as well as studies
in combination with checkpoint inhibitors and targeted and IMiD
therapies in solid and hematological malignancies. For further
information about Oncolytics, please
visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended and forward-looking information under applicable
Canadian securities laws (such forward-looking statements and
forward-looking information are collectively referred to herein as
"forward-looking statements"). Forward-looking statements,
including the Company's belief as to the potential of
REOLYSIN® as a cancer therapeutic; the anticipated
benefits of the formation of the Scientific Advisory Board to the
Company; the composition of the Scientific Advisory Board; the
Company's plans regarding its first registration study in
metastatic breast cancer and studies in combination with checkpoint
inhibitors and IMiD therapies in solid and hematological
malignancies; and other statements related to anticipated
developments in the Company's business and technologies involve
known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
research and development projects, the efficacy of REOLYSIN as a
cancer treatment, the success and timely completion of clinical
studies and trials, the Company's ability to successfully
commercialize REOLYSIN, uncertainties related to the research and
development of pharmaceuticals, uncertainties related to the
regulatory process and general changes to the economic environment.
Investors should consult the Company's quarterly and annual filings
with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing
undue reliance on forward-looking statements. The Company does not
undertake to update these forward-looking statements, except as
required by applicable laws.
SOURCE Oncolytics Biotech Inc.